Roche's Gazyvaro Receives Backing of EU's CHMP for CLL

EU's Committee for Medicinal Products for Human Use (CHMP)supported the use of Gazyvaro based on the phase III CLL11 study, wherein treatment with Gazyvaro (obinutuzumab) plus chlorambucil significantly reduced the risk of disease worsening or death by 86% and increased survival time for previously untreated CLL patients compared to those who received treatment with chlorambucil alone.
Published Online: May 23, 2014

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who have comorbidities making them unsuitable for a certain type of chemotherapy (full-dose fludarabine). Gazyvaro is marketed as Gazyva in the U.S. and the rest of the world.

“We are delighted the CHMP has recognized the strength of the Gazyvaro data established in the CLL11 study,” said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head, Global Product Development. “Typically, around half of patients diagnosed with CLL have comorbidities that make full-dose fludarabine based treatment unsuitable for them. We are pleased to be one step closer to making Gazyvaro available as a new foundation of treatment for their disease.”

Press release: http://bit.ly/RZZbaz

Source: Roche



Feature
Recommended Articles
The deal combines Humana's 3.2 million Medicare enrollees with Aetna's 1.26 million Medicare enrollees, giving the new combined company a strong position as the baby boomer population ages.
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Metastatic colorectal cancer patients with higher body mass index (BMI) outlived patients with the lowest BMI by an average of 2-and-a-half months, according to new data presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer 2015.